MOTS-c Clinical Trials Status 2026

MOTS-c Clinical Trials Status 2026. MOTS-c peptide clinical trials for 2025-2026, including CB4211 Phase 1 results, FDA status, WADA status, and research pipeline. Key Takeaways MOTS-c is NOT FDA approved: No completed large-scale human clinical trials exist as of March 2026 — all therapeutic claims remain preclinical CB4211 Phase 1 showed promise: CohBar's MOTS-c analog demonstrated safety and reduced liver fat markers (ALT -21%, AST -28%) in obese subjects with fatty liver disease Phase 2 development stalled: CB4211 clinical development was discontinued, and no new MOTS-c-based drugs have entered Phase 2 trials WADA banned MOTS-c in 2024: Added to the Prohibited List as an AMPK activator due to its exercise-mimetic properties Strong preclinical data: Animal studies show improved insulin sensitivity, reduced obesity, anti-aging effects, and diabetes prevention Delivery remains a barrier: Reliable delivery systems for mitochondrial-derived peptides are still lacking, limiting clinical translation Introduction: What Is MOTS-c? MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by the mitochondrial genome — specifically by the MT-RNR1 gene. First identified by Dr. Changhan David Lee's lab at the University of Southern California in 2015, MOTS-c is part of a class of signaling molecules called mitochondrial-derived peptides (MDPs) . What makes MOTS-c uniquely interesting to researchers is its role as an exercise mimetic — a compound that can replicate some of the metabolic benefits of physical exercise at the cellular level. MOTS-c is naturally upregulated during exercise, translocates to the cell nucleus under metabolic stress, and activates genes involved in energy regulation and stress adaptation. For researchers tracking MOTS-c clinical trials status in 2026, the picture is complex: extraordinary preclinical promise in mice paired with limited — and now stalled — human trial data. This article covers everything currently known about MOTS-c's clinical pipeline, the CB4211 trial results, FDA regulatory standing, and what the future may hold. Common searches like MOTS-c clinical trials 2026 , MOTS-c peptide human clinical trials 2025 2026 , MOTS-c peptide research 2025 2026 study , MOTS-c peptide benefits research studies 2025 2026 , MOTS-c human clinical trials results 2025 2026 , and MOTS-c human clinical trials 2025 2026 all point to the same evidence base: CB4211 Phase 1a/1b results, no active Phase 2 or Phase 3 MOTS-c program, and no FDA-approved MOTS-c drug. MOTS-c Mechanism of Action Understanding MOTS-c's mechanism is essential context for evaluating its clinical trial data. The peptide operates through a well-characterized pathway: The Folate-AICAR-AMPK Pathway MOTS-c's primary mechanism targets the folate-methionine cycle and the tethered de novo purine biosynthesis pathway . By inhibiting the folate cycle, MOTS-c causes an accumulation of endogenous AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) within cells. AICAR is a potent activator of AMP-activated protein kinase (AMPK) — the same master metabolic regulator targeted by metformin, the first-line diabetes drug. This AMPK activation cascade triggers multiple downstream effects: Enhanced glucose uptake in skeletal muscle independent of insulin signaling Increased fatty acid oxidation and improved mitochondrial respiration Reduced inflammation through suppression of NF-κB signaling Nuclear translocation under metabolic stress to regulate stress-responsive gene expression Exercise Mimetic Properties Human studies have confirmed that exercise increases MOTS-c levels in both skeletal muscle and blood circulation. This bidirectional relationship — exercise produces MOTS-c, and MOTS-c replicates some exercise benefits — is what earned the peptide its "exercise mimetic" designation. Researchers have described MOTS-c as sharing physiological similarities with metformin in terms of regulating glucose utilization, mitochondrial metabolism, fatty acid metabolism, and body weight. CB4211: The First MOTS-c Clinical Trial in Humans The most significant clinical data on MOTS-c comes from CB4211 , a synthetic MOTS-c analog developed by CohBar, Inc. and tested under ClinicalTrials.gov identifier NCT03998514 . Researchers searching for "CB4211 MOTS-c analog clinical trial results", "CB4211 MOTS-c analog phase 1 trial", or "ClinicalTrials.gov MOTS-c CB4211" will find the same dataset summarized below. Phase 1a Results (2019) The Phase 1a trial enrolled healthy non-obese volunteers to assess safety, tolerability, and pharmacokinetics. The trial was initially paused in 2018 due to persistent mild injection site reactions, then resumed under an amended protocol and completed in 2019. Outcome: CB4211 was found to be safe and well-tolerated after 7 days of dosing Injection site reactions: Mild and manageable with the amended protocol Milestone: First mitochondrial-derived peptide therapeutic to complete human testing Phase 1b Results (2021) The Phase 1b portion was a 4-week, multi-center, randomized, double-blind, placebo-controlled study in 20 obese subjects with non-alcoholic fatty liver disease (NAFLD). Results presented at the American Association for the Study of Liver Diseases (AASLD) 2021 conference showed: Biomarker Change vs. Placebo Clinical Significance Serum ALT -21% Liver damage marker improvement Serum AST -28% Liver damage marker improvement Fasting Glucose -6% Metabolic improvement Body Weight Trend toward reduction Promising but not statistically significant at 4 weeks The study met its primary endpoint: CB4211 was well-tolerated with no serious adverse events. These results were particularly promising because meaningful biomarker changes occurred after only four weeks of treatment. Why CB4211 Development Stalled Despite these encouraging Phase 1 results, CB4211 did not advance to Phase 2 trials . CohBar faced financial and operational challenges that led to the discontinuation of the program. As of March 2026, no other company has publicly announced plans to bring a MOTS-c analog into Phase 2 clinical testing. This represents one of the major frustrations for researchers following MOTS-c clinical trials — a compound with strong preclinical data and promising early human safety results that has not yet found a development partner to advance it through the regulatory pipeline. Current MOTS-c Clinical Trial Landscape (2026) As of March 2026, the MOTS-c clinical trials status can be summarized as follows: Trial / Program Phase Status Indication CB4211 (CohBar) Phase 1a/1b Completed — development discontinued NASH & Obesity MOTS-c (direct) N/A No active IND applications N/A Next-gen MDP analogs Preclinical Academic research ongoing Diabetes, sarcopenia, aging There are no active Phase 2 or Phase 3 clinical trials for MOTS-c or any MOTS-c analog registered on ClinicalTrials.gov. The gap between preclinical promise and clinical translation remains significant, primarily due to delivery system challenges and the lack of pharmaceutical company investment in mitochondrial-derived peptide therapeutics. ClinicalTrials.gov and NCT03998514 Status ClinicalTrials.gov MOTS-c peptide searches currently point back to CB4211 rather than an unmodified MOTS-c peptide trial. The relevant listing, NCT03998514 , is a completed CohBar Phase 1a/1b study of CB4211 in healthy non-obese volunteers and subjects with NAFLD. As of the current ClinicalTrials.gov record, this trial is completed, not recruiting, and does not represent an active 2025-2026 MOTS-c human trial. MOTS-c FDA Approval Status MOTS-c is NOT FDA approved for any human therapeutic use. There is no active Investigational New Drug (IND) application for MOTS-c or any MOTS-c analog as of 2026. The MOTS-c FDA approval status 2026 remains unapproved. Researchers searching for FDA approval status of MOTS-c peptide or MOTS-c FDA status 2026 should treat the compound as a research-stage mitochondrial-derived peptide, not as an approved medication or active late-stage clinical candidate. For MOTS-c human clinical trials results 2024 2025 2026 and MOTS-c human clinical trials results 2025 or 2026 , CB4211 remains the central human dataset. Separate searches for MOTS-c peptide latest research 2025 2026 should be read as preclinical and observational research updates unless a new registered trial sponsor emerges. As a biologic agent, MOTS-c would be regulated under the FDA's IND framework, which requires comprehensive preclinical evaluation — including pharmacokinetics, toxicology, and immunogenicity studies — before advancing through phased clinical trials. Given that only Phase 1 data exists (from an analog, not MOTS-c itself), the peptide is years away from any potential FDA approval pathway even in the best-case scenario. Researchers searching for the FDA approval status of MOTS-c should also distinguish direct MOTS-c human exposure data from CB4211 analog data . CB4211 provides the only meaningful human clinical trial results in the 2024-2026 window, but it is a modified MOTS-c analog rather than the unmodified MOTS-c peptide sold by research suppliers. The FDA has not reviewed unmodified MOTS-c as an approved drug, and ClinicalTrials.gov does not currently list an active MOTS-c peptide trial in humans. For FDA MOTS-c no human exposure data searches, FDA's compounding safety-risk materials say the agency has not identified human exposure data for drug products containing MOTS-c administered by any route. That statement applies to MOTS-c drug products reviewed in the compounding context; it should not be confused with the separate CB4211 analog Phase 1 dataset, which involved a modified MOTS-c-derived candidate rather than unmodified MOTS-c. For a comprehensive overview of which peptides currently have FDA approval, see our complete FDA Approved Peptides List 2026 . WADA Ban: MOTS-c Prohibited in Sport Since 2024 The World Anti-Doping Agency (WADA) explicitly added MOTS-c to its Prohibited List beginning January 1, 2024 . The peptide was classified as an example of an AMP-activated protein kinase (AMPK) activator under Section S4 (Hormone and Metabolic Modulators). This ban reflects MOTS-c's exercise-mimetic properties — its ability to enhance metabolic performance through AMPK activation essentially makes it a performance-enhancing substance in competitive athletics. Athletes who test positive for exogenous MOTS-c face anti-doping violations regardless of the compound's unapproved medical status. The WADA ban is notable because it occurred before FDA approval, meaning MOTS-c is prohibited in sport despite never being approved as a drug — an unusual regulatory situation that underscores how seriously anti-doping authorities view the compound's metabolic effects. The MOTS-c WADA status 2026 remains unchanged: prohibited in-competition and out-of-competition under Section S4. Note that no ClinicalTrials.gov MOTS-c obesity trial is currently active outside the completed CB4211 NAFLD/obesity Phase 1b — searches expecting a new registered MOTS-c obesity trial will not find one in the 2025-2026 listings. USADA follows the WADA Prohibited List for athletes under its jurisdiction, so the MOTS-c WADA banned status 2026 and USADA athlete-risk answer are effectively the same: MOTS-c is a prohibited peptide for tested athletes, even though it has no completed large-scale human clinical trials and no FDA approval. Preclinical Research Highlights (2024-2026) While clinical trials have stalled, preclinical research on MOTS-c continues to produce compelling results: For MOTS-c latest research 2025 2026 searches, the current updates are mainly preclinical, observational, and mechanistic. They do not change the clinical-trial conclusion: CB4211 remains the only meaningful human MOTS-c-analog trial, and unmodified MOTS-c still lacks an active registered human development program. Diabetes Prevention A 2025 study published in Experimental & Molecular Medicine demonstrated that MOTS-c treatment prevents pancreatic beta-cell senescence in mouse models of both type 1 and type 2 diabetes. Systemic MOTS-c administration reduced markers of cellular aging in pancreatic islets and improved glucose tolerance — suggesting the peptide may protect the insulin-producing cells that deteriorate in diabetes. Cardiovascular Protection Research published in Frontiers in Physiology (2025) showed that MOTS-c restores mitochondrial respiration in type 2 diabetic hearts , improving cardiac function in diabetic rat models by enhancing glucose metabolism and upregulating antioxidant defense systems. Anti-Aging & Sarcopenia MOTS-c has been shown to reduce myostatin and muscle atrophy signaling in aging models, with implications for treating age-related muscle loss (sarcopenia). The peptide's ability to improve mitochondrial function — which naturally declines with age — positions it as a potential intervention for multiple aging-related conditions. Obesity & Insulin Resistance The foundational 2015 study in Cell Metabolism established that MOTS-c promotes metabolic homeostasis, drives weight loss, and reduces both obesity and insulin resistance in high-fat-diet-fed mice — though human research has not yet confirmed whether MOTS-c can help lose weight in clinical trials. Subsequent human observational studies have shown that: Obese children have significantly lower circulating MOTS-c levels Plasma MOTS-c levels in men are negatively correlated with fasting insulin, HbA1c, and BMI An Asian-specific mitochondrial DNA variant (m.1382A>C) that alters MOTS-c structure is associated with higher type 2 diabetes prevalence in males (meta-analysis of 27,527 subjects) MOTS-c vs. Other Metabolic Peptides To understand where MOTS-c sits in the broader peptide research landscape, it helps to compare it with other metabolic peptides at various stages of development: Peptide Target FDA Status Clinical Stage Semaglutide GLP-1 receptor Approved (2017) Post-market Tirzepatide GIP/GLP-1 receptors Approved (2022) Post-market Retatrutide GIP/GLP-1/Glucagon Not approved Phase 3 Survodutide Glucagon/GLP-1 Not approved Phase 3 MOTS-c AMPK (via folate cycle) Not approved Phase 1 (stalled) Elamipretide Mitochondria (cardiolipin) Approved (2025) Post-market MOTS-c's unique AMPK-based mechanism differentiates it from the GLP-1 receptor agonists that dominate today's metabolic drug market. However, while GLP-1 drugs have moved rapidly through clinical development backed by major pharmaceutical companies, MOTS-c's path has been limited by smaller development partners and delivery challenges. For another mitochondrial-derived peptide comparison point, see the Humanin peptide product page . Safety Profile: What the Data Shows Based on the limited human trial data from CB4211: Well-tolerated: No serious adverse events reported in Phase 1a or 1b Injection site reactions: Mild, persistent reactions were the primary concern — significant enough to temporarily halt the Phase 1a trial for protocol amendment Short-term safety: Acceptable safety over 4 weeks of treatment in the Phase 1b study However, several critical unknowns remain: Long-term safety: No data beyond 4 weeks of human exposure exists Drug interactions: CYP pathway effects are uninvestigated in humans Immunogenicity: As a mitochondrial-derived peptide, long-term immune response data is needed Dose-response: Optimal therapeutic dosing in humans has not been established Researchers should note that the peptide sold as "MOTS-c" by research chemical suppliers is not identical to CB4211 (which was a modified analog). Safety data from CB4211 trials may not directly apply to unmodified MOTS-c. Researchers comparing current lab supply options can review our MOTS-c product page for third-party tested compounds. Barriers to Clinical Translation Several key obstacles explain why MOTS-c clinical trials have not progressed despite strong preclinical data: Delivery systems: Reliable delivery methods for mitochondrial-derived peptides remain underdeveloped. MOTS-c's small size and peptide nature create bioavailability challenges typical of injectable peptide therapeutics. Pharmaceutical investment: CohBar's inability to fund Phase 2 trials left the MOTS-c therapeutic space without a major development partner. Large pharma companies have focused investment on the more commercially proven GLP-1 class. Regulatory pathway: As a novel biologic, MOTS-c faces the full IND regulatory framework, including extensive preclinical toxicology requirements that are costly for small biotech firms. Competition: The spectacular clinical success of semaglutide, tirzepatide, and incoming triple agonists like retatrutide for metabolic indications makes the investment case for an earlier-stage competitor harder to justify. Future Outlook: What to Watch in 2026-2027 Despite the stalled clinical pipeline, several developments could reignite MOTS-c clinical research: Academic collaborations: University research groups continue publishing new mechanisms and therapeutic applications, building the scientific case for industry re-engagement Novel delivery platforms: Advances in peptide delivery (nanoparticles, oral formulations, depot injections) could solve the bioavailability problem that has limited clinical development Combination therapies: MOTS-c's unique AMPK mechanism makes it a potential complement to GLP-1 agonists rather than a direct competitor — a combination strategy could attract pharma interest Aging indications: Growing investment in longevity medicine may create new funding pathways for mitochondrial-targeted therapeutics ME/CFS research: A 2025 preprint proposed redefining mitochondrial therapy for ME/CFS (chronic fatigue syndrome) using MOTS-c, potentially opening a new indication pathway Frequently Asked Questions Is MOTS-c FDA approved? No. MOTS-c is not FDA approved for any therapeutic use. There are no active IND applications or ongoing FDA-registered clinical trials for MOTS-c as of March 2026. For a parallel regulatory review of another unapproved research peptide, see our TB-500 FDA approval status breakdown . What happened to the CB4211 clinical trial? CohBar completed Phase 1a (safety in healthy volunteers) and Phase 1b (efficacy in obese/NAFLD patients) studies of CB4211 between 2019-2021. The results were positive — showing safety, tolerability, and meaningful reductions in liver damage markers. However, the program was discontinued before advancing to Phase 2, likely due to CohBar's financial and operational challenges. Why is MOTS-c banned by WADA? MOTS-c was added to the WADA Prohibited List in 2024 as an AMPK activator under the Hormone and Metabolic Modulators category. Its exercise-mimetic properties — the ability to enhance glucose uptake and metabolic efficiency through AMPK activation — qualify it as a performance-enhancing substance in competitive sport. Is MOTS-c the same as metformin? No, but they share mechanistic similarities. Both MOTS-c and metformin activate AMPK, though through different upstream pathways. MOTS-c inhibits the folate cycle to accumulate AICAR (an AMPK activator), while metformin primarily inhibits mitochondrial complex I. Researchers have described MOTS-c as sharing "physiological similarities" with metformin in terms of regulating glucose utilization and body weight. When might MOTS-c get FDA approval? There is no clear timeline for MOTS-c FDA approval. With no active clinical trial programs, the compound would need a new pharmaceutical sponsor, additional preclinical work, and successful Phase 1-3 trials before any approval could occur. Even optimistically, this process would take 7-10+ years from the current starting point. Can I buy MOTS-c for research? MOTS-c is available from research chemical suppliers for laboratory and research use only . It is not approved for human therapeutic use. Research-grade MOTS-c is not equivalent to the CB4211 analog tested in clinical trials. Browse our MOTS-c product page for lab-tested options with third-party COA documentation. Disclaimer: This article is for informational and educational purposes only. All compounds referenced are intended for laboratory and research use only. Not for human consumption. PeptideStack is an independent informational resource and does not sell, manufacture, or distribute any peptides. Some links in this article are affiliate links, and PeptideStack may earn a commission at no extra cost to you. Always consult applicable institutional guidelines and regulations before conducting research with any compound. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.